Nigerian participants receive Lassa fever virus vaccine in Phase II trial
The trial will assess the safety, tolerability, and immunogenicity of varying dosages of the vaccine.
The trial will assess the safety, tolerability, and immunogenicity of varying dosages of the vaccine.